2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events A 2024 Meta-analysis of 13 multiple cardiovascular outcome trials has documented that GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
Benefits include: Larger treatment area Useful for long-term site rotation May be more comfortable for some individuals Peptide Injection Site Comparison Can You Inject Peptides in Your Stomach
Shelf Life: The production date and shelf life are shown on the box
In normal individual, 75 to 80% of administered phenacetin is rapidly metabolized to acetaminophen
There was a significant average paired fold change in the levels of several GPs 1 week after 4-week intermittent fasting compared with the levels at the end of 4th week during 4-week intermittent fasting (Supplementary Table S3)
When you understand how GLP-1 medications work, you will be better able to appreciate their possible benefits
